AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32029499 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg folic acid with 60 mg iron weekly for 16 weeks
Number of subjects: 300
Study 32029499 — intervention group
Group type: COMPARATOR
Intervention: 0.0 mg (placebo) folic acid with 60 mg iron weekly for 16 weeks
Number of subjects: 300
Study 33278329 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scans
Number of subjects: 450
Study 32074418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab (0.5 mg/kg, subcutaneously at baseline, week 4, and week 8)
Number of subjects: 70
Study 32074418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32074418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Number of subjects: 70
Study 34582636 — intervention group
Group type: EXPERIMENTAL
Intervention: Unani formulation
Number of subjects: 72
Study 34582636 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone 4% (Control)
Number of subjects: 72
Study 33649972 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week spa therapy with low-dose radon therapy
Number of subjects: 25
Study 33649972 — intervention group
Group type: COMPARATOR
Intervention: 2-week spa therapy without radon therapy
Number of subjects: 25
Study 33649972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without radon therapy)
Number of subjects: 25
Study 32065766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 17922
Study 32065766 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 17922
Study 35866644 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental schedule group (n=192) reviewed in a reduced-frequency schedule
Number of subjects: 388
Study 35866644 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule group (control: n=196) reviewed as per current national guidelines
Number of subjects: 388
Study 35866644 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental schedule group (n=192)
Number of subjects: 388
Study 35866644 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule group (control: n=196)
Number of subjects: 388
Study 34544847 — intervention group
Group type: EXPERIMENTAL
Intervention: TipsByText intervention, 3 times a week for 7 months
Number of subjects: 644
Study 32299999 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin training (60 min per session, 3 sessions per week for 24 weeks)
Number of subjects: 102
Study 32299999 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity control group (health education for 30 min at least once a month)
Number of subjects: 102
Study 34495379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prediction model based on parametrium invasion, lymph node metastasis, and oviduct metastasis.
Number of subjects: 1496
Study 34495379 — intervention group
Group type: COMPARATOR
Intervention: Nomogram prediction model
Number of subjects: 1496
Study 33821958 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led, mHealth-based intervention
Number of subjects: 136
Study 33821958 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study 36280642 — intervention group
Group type: EXPERIMENTAL
Intervention: Crofelemer 125 mg orally twice daily during chemotherapy cycles 1 and 2
Number of subjects: 51
Study 36280642 — intervention group
Group type: COMPARATOR
Intervention: Control (no scheduled prophylactic medication)
Number of subjects: 51
Study 33197084 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Chronically relapsing brain disease'
Number of subjects: 3635
Study 33197084 — intervention group
Group type: COMPARATOR
Intervention: 'Problem' (control)
Number of subjects: 3635
Study 33197084 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (male vs female)
Number of subjects: 3635
Study 32934365 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel anticancer agents and combination therapies
Number of subjects: 0
Study 32934365 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent or combination therapies
Number of subjects: 0
Study 32934365 — intervention group
Group type: COMPARATOR
Intervention: Multiple agents in a head-to-head comparison
Number of subjects: 0
Study 32037096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual (SL) administration of edaravone 60 mg
Number of subjects: 0
Study 32037096 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) infusion of edaravone 60 mg
Number of subjects: 0
Study 34923134 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 99
Study 34923134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 33058438 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (4-6 mg/kg/day)
Number of subjects: 86
Study 33058438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 32487575 — intervention group
Group type: EXPERIMENTAL
Intervention: Eco-directed sustainable prescribing (EDSP)
Number of subjects: 405
Study 32487575 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSP practices
Number of subjects: 405
Study 32487575 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSP and EPV awareness
Number of subjects: 405
Study 32487575 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes towards EDSP
Number of subjects: 405
Study 32487575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prescribing and environment-friendly drug profiles
Number of subjects: 405
Study 33315716 — intervention group
Group type: EXPERIMENTAL
Intervention: High perirenal fat surface area (fourth quartile)
Number of subjects: 733
Study 33315716 — intervention group
Group type: EXPERIMENTAL
Intervention: Perirenal fat surface area (cm² increase)
Number of subjects: 733
Study 33315716 — intervention group
Group type: COMPARATOR
Intervention: Perirenal fat surface area categories
Number of subjects: 733
Study 33176887 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus bevacizumab (10 mg/kg each i.v.)
Number of subjects: 26
Study 35843115 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-linguistic programming (NLP)
Number of subjects: 0
Study 35843115 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33554299 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally assisted vitreoretinal system (DAVS)
Number of subjects: 60
Study 33554299 — intervention group
Group type: COMPARATOR
Intervention: Conventional analog microscope (CAM)
Number of subjects: 60
Study 33554299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DAVS and CAM
Number of subjects: 60
Study 33554299 — intervention group
Group type: EXPERIMENTAL
Intervention: DAVS
Number of subjects: 60
Study 33554299 — intervention group
Group type: COMPARATOR
Intervention: CAM
Number of subjects: 60
Study 33534791 — intervention group
Group type: EXPERIMENTAL
Intervention: MB66 film (Active)
Number of subjects: 38
Study 33534791 — intervention group
Group type: COMPARATOR
Intervention: Placebo film (Control)
Number of subjects: 38
Study 32008572 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush with a monitor to visualise red‐fluorescent dental plaque (monitor usage group, n = 10)
Number of subjects: 20
Study 32008572 — intervention group
Group type: COMPARATOR
Intervention: Electric toothbrush without a monitor (monitor‐non‐use group, n = 10)
Number of subjects: 20
Study 32008572 — intervention group
Group type: COMPARATOR
Intervention: Comparison of monitor usage group vs monitor non-use group
Number of subjects: 20
Study 35556386 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg/daily for 6 weeks)
Number of subjects: 10
Study 35556386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 10
Study 32512067 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC)
Number of subjects: 38
Study 32512067 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 38
Study 32512067 — intervention group
Group type: COMPARATOR
Intervention: Positive control (no medicament)
Number of subjects: 38
Study 35639828 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 828
Study 35639828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 828
Study 33563235 — intervention group
Group type: COMPARATOR
Intervention: DePuy Synthes® one‐third semitubular plate (Group I)
Number of subjects: 45
Study 33563235 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWCLIP TECHNICS, Active Ankle® polyaxial locking plate (Group II)
Number of subjects: 45
Study 33132656 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate matter with a diameter ≤ 2.5 μm (PM2.5)
Number of subjects: 20071900
Study 33132656 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon monoxide (CO)
Number of subjects: 20071900
Study 33132656 — intervention group
Group type: EXPERIMENTAL
Intervention: Average temperature
Number of subjects: 20071900
Study 33132656 — intervention group
Group type: EXPERIMENTAL
Intervention: Air pollutants
Number of subjects: 20071900
Study 33132656 — intervention group
Group type: EXPERIMENTAL
Intervention: Time lag of MFAPs exposure
Number of subjects: 20071900
Study 34446476 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of oxytocin
Number of subjects: 720
Study 34446476 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex of the neonate
Number of subjects: 720
Study 34446476 — intervention group
Group type: EXPERIMENTAL
Intervention: Primigravidity
Number of subjects: 720
Study 34446476 — intervention group
Group type: EXPERIMENTAL
Intervention: Meconium-stained liquor
Number of subjects: 720
Study 32869813 — intervention group
Group type: EXPERIMENTAL
Intervention: Test breakfasts with increasing viscosity of konjac glucomannan (KGM)
Number of subjects: 22
Study 32869813 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (one of the four test breakfasts)
Number of subjects: 22
Study 35781080 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP-Ed intervention
Number of subjects: 97
Study 35781080 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 33506447 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0
Study 33506447 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids (cumulative 4-5 g) + orbital irradiation
Number of subjects: 0
Study 33506447 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents
Number of subjects: 0
Study 33506447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bony orbital decompression
Number of subjects: 0
Study 33506447 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab (IGF-1 receptor antibody)
Number of subjects: 0
Study 32191722 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin administration (24 IU)
Number of subjects: 88
Study 32191722 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned oxytocin (24 IU with CS during acquisition days, placebo with CS during evocation days)
Number of subjects: 88
Study 32191722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 35238041 — intervention group
Group type: EXPERIMENTAL
Intervention: NSPT with 1% melatonin gel
Number of subjects: 22
Study 35238041 — intervention group
Group type: COMPARATOR
Intervention: NSPT with placebo gel
Number of subjects: 22
Study 34121140 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day for 1 week, then 6 mg/day for 7 weeks)
Number of subjects: 103
Study 34121140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to melatonin)
Number of subjects: 103
Study 34121140 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 103
Study 34121140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 32208439 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (beta-blocker)
Number of subjects: 242
Study 32208439 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 242
Study 32208439 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 242
Study 32208439 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor antagonist
Number of subjects: 242
Study 32208439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 32487568 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 0
Study 36156195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral anodal tDCS stimulation over left and right cerebellar hemispheres, 10 sessions (20-min duration, five sessions per week)
Number of subjects: 36
Study 36156195 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 36
Study 33370571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (2000 mg)
Number of subjects: 45
Study 33067293 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy House intervention (six weekly 90 min school-based group sessions)
Number of subjects: 1204
Study 33067293 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum (control group)
Number of subjects: 1204
Study 33067293 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy House intervention
Number of subjects: 1204
Study 37732870 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM with personalized feedback (ESM-f)
Number of subjects: 124
Study 37732870 — intervention group
Group type: EXPERIMENTAL
Intervention: ESM alone (ESM)
Number of subjects: 124
Study 37732870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional intervention)
Number of subjects: 124
Study 33667406 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 460
Study 33667406 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 460
Study 32769877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotics (3 months duration)
Number of subjects: 140
Study 32769877 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise therapy (control group)
Number of subjects: 140
Study 34808006 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol air polishing (test group)
Number of subjects: 57
Study 34808006 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked cotton gauzes (control group)
Number of subjects: 57
Study 34808006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 32161056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 0
Study 32161056 — intervention group
Group type: COMPARATOR
Intervention: History of breast cancer
Number of subjects: 0
Study 32161056 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen treatment for breast cancer
Number of subjects: 0
Study 32161056 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitors treatment for breast cancer
Number of subjects: 0
Study 35727103 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Worsening (HFW)
Number of subjects: 12753
Study 32100634 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion induction (educational prompts and compassionate perspective writing)
Number of subjects: 141
Study 32100634 — intervention group
Group type: COMPARATOR
Intervention: Control condition (verbal learning only)
Number of subjects: 141
Study 35292492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track referral for early intervention on psychosocial and behavioural risk factors (smoking, alcohol consumption, depression, physical violence)
Number of subjects: 2832
Study 35292492 — intervention group
Group type: COMPARATOR
Intervention: Local standard of care for risk factors
Number of subjects: 2832
Study 35292492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track referral for early intervention
Number of subjects: 2832
Study 34897651 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 32
Study 33004384 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention package to support clinicians and patients to amend incorrect penicillin allergy records.
Number of subjects: 0
Study 33004384 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention package materials developed based on barriers identified.
Number of subjects: 0
Study 35599320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 418
Study 35599320 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 418
Study 33650758 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-020
Number of subjects: 120
Study 33650758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35470582 — intervention group
Group type: EXPERIMENTAL
Intervention: TightRope® system
Number of subjects: 18
Study 35470582 — intervention group
Group type: COMPARATOR
Intervention: TightRope®
Number of subjects: 18
Study 35470582 — intervention group
Group type: COMPARATOR
Intervention: IS screw
Number of subjects: 18
Study 32770730 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4831 15 mg
Number of subjects: 13
Study 32770730 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4831 45 mg
Number of subjects: 13
Study 32770730 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4831
Number of subjects: 13
Study 32546973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg alone once daily for seven days (Period I)
Number of subjects: 36
Study 32546973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg with linagliptin 20 mg for seven days (Period II)
Number of subjects: 36
Study 32546973 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 20 mg alone once daily for seven days (Period I)
Number of subjects: 36
Study 32546973 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 20 mg with fimasartan 120 mg for seven days (Period II)
Number of subjects: 36
Study 33290915 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT plus pharmacotherapy
Number of subjects: 111
Study 33290915 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 111
Study 32925028 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication for agitation related to dementia
Number of subjects: 801
Study 32925028 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological therapy
Number of subjects: 801
Study 35294524 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cryotherapy (Arm A)
Number of subjects: 288
Study 35294524 — intervention group
Group type: COMPARATOR
Intervention: Cytology-based screening (Arm B)
Number of subjects: 288
Study 32958459 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMatrix stents
Number of subjects: 2341
Study 32958459 — intervention group
Group type: COMPARATOR
Intervention: Orsiro stents
Number of subjects: 2341
Study 35956288 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-protein plus glucose (240 kcal)
Number of subjects: 20
Study 35956288 — intervention group
Group type: COMPARATOR
Intervention: Glucose (120 kcal)
Number of subjects: 20
Study 35956288 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-protein (120 kcal)
Number of subjects: 20
Study 35956288 — intervention group
Group type: COMPARATOR
Intervention: Control (2 kcal)
Number of subjects: 20
Study 34377456 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation (RFD) for low back pain
Number of subjects: 14
Study 34377456 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations on the RFD technique
Number of subjects: 14
Study 35344191 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide 1 mg
Number of subjects: 0
Study 35344191 — intervention group
Group type: COMPARATOR
Intervention: Once-daily canagliflozin 300 mg
Number of subjects: 0
Study 32234610 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental communication about alcohol
Number of subjects: 269
Study 35089070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal swab with vibration (Tc group)
Number of subjects: 34
Study 35089070 — intervention group
Group type: COMPARATOR
Intervention: Nasal swab without vibration (Ct group)
Number of subjects: 34
Study 34406248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar technique
Number of subjects: 55
Study 34406248 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal technique
Number of subjects: 55
Study 33211508 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleable mindset intervention
Number of subjects: 292
Study 33211508 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms intervention
Number of subjects: 292
Study 33211508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of malleable mindset and social norms
Number of subjects: 292
Study 33211508 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 292
Study 33211508 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 292
Study 35113595 — intervention group
Group type: EXPERIMENTAL
Intervention: Research‐to‐Policy Collaboration (RPC) model
Number of subjects: 0
Study 35113595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33982202 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-based segmentation
Number of subjects: 49
Study 33982202 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 49
Study 33711209 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT OPEN
Number of subjects: 38
Study 33711209 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 38
Study 32648534 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120
Study 32648534 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 120
Study 34030219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at the p6 point for 10 minutes in both hands, twice a day for two consecutive days.
Number of subjects: 64
Study 34030219 — intervention group
Group type: COMPARATOR
Intervention: Inactive acupressure at the thumb hands at the same time points as the intervention group.
Number of subjects: 64
Study 36247107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait Resistance Training (GRT)
Number of subjects: 26
Study 36247107 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability Resistance Training (SRT)
Number of subjects: 26